Trump announces trade deal with EU following months of negotiations
CARLSBAD, California - Palisade Bio, Inc. (NASDAQ:PALI), a clinical-stage biopharmaceutical company focused on autoimmune, inflammatory, and fibrotic diseases, announced Wednesday the appointment of Emil Chuang, MB BS FRACP to its Board of Directors. The company, currently valued at $3.5 million, maintains a strong liquidity position with a current ratio of 2.84x, indicating robust short-term financial stability.InvestingPro analysis reveals multiple key insights about Palisade Bio’s financial position, with 10+ additional ProTips available to subscribers.
Dr. Chuang brings nearly 25 years of pharmaceutical and clinical experience to the company. His background includes leadership roles in drug development programs that led to two regulatory approvals: infliximab for pediatric Crohn’s disease and lorcaserin for morbid obesity.
Currently serving as Chief Medical Officer at Intrinsic Medicine, Dr. Chuang previously held positions at Nestlé Health Science, Takeda, and Progenity. His expertise spans preclinical translational medicine through Phase 1-4 clinical development, with significant contributions to inflammatory bowel disease (IBD) programs.
With two analysts recently revising their earnings estimates upward for the upcoming period, and price targets ranging from $2 to $16, the company shows potential despite current challenges. "His extensive clinical development experience and deep understanding of IBD will provide valuable insight as we continue to execute our clinical programs," said JD Finley, Chief Executive Officer of Palisade Bio, in a press release statement.
Dr. Chuang completed his medical degree at the University of Sydney, Australia, and his pediatrics specialty training in Australia before completing subspecialty training in pediatric gastroenterology and nutrition in the United States. He has authored more than 80 peer-reviewed publications, abstracts, and book chapters.
Palisade Bio is developing PALI-2108, which targets Fibrostenotic Crohn’s Disease and Ulcerative Colitis. The company aims to transform treatment landscapes for patients with autoimmune, inflammatory, and fibrotic diseases through its novel therapeutics approach. According to InvestingPro, the company maintains more cash than debt on its balance sheet, providing financial flexibility for its development programs. Current analysis suggests the stock may be undervalued based on InvestingPro’s Fair Value calculations.
In other recent news, Palisade Bio has announced positive results from its Phase 1 trials for PALI-2108, a drug aimed at treating fibrostenotic Crohn’s disease and moderate to severe ulcerative colitis. The trials met their primary endpoints of safety, tolerability, and pharmacokinetics, with no serious adverse events reported. This announcement follows the company’s presentation of promising preclinical data at Digestive Disease Week 2025, where PALI-2108 was shown to effectively reduce inflammation markers in a mouse model of colitis. The drug also demonstrated favorable absorption and bioavailability in pharmacokinetic modeling, supporting its potential for clinical use. As part of its ongoing efforts, Palisade Bio has completed the Phase 1a portion of its study and is progressing with the Phase 1b cohort. Topline data from the Phase 1a study is anticipated by the end of May 2025. The company is focused on advancing PALI-2108 through further clinical development, with plans to initiate a Phase 1b cohort to explore additional safety and efficacy aspects. Palisade Bio continues to develop novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, with a keen interest in transforming treatment landscapes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.